Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Stem Cell / Bone Marrow Transplant : high-risk solid tumors and lymphomas
This is a research study investigating the addition of Haploidentical natural killer cell infusion to autologous stem cell transplantation. This will be evaluated in participants with high-risk solid tumors for whom autologous transplantation is indicated.
Eligibility criteria, among others, include:
Stem Cell Transplant Recipient:
Stem Cell Collection Phase
Autologous Stem Cell Transplant Phase
HAPLO NK Cell DONOR:
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
David Shook, MDSt. Jude Children’s Research Hospital
Referring or consulting physicians only: firstname.lastname@example.org
For all other inquiries about St. Jude Children's Research Hospital studies: email@example.com
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.